Cat. No.: DIA-0243124
Product Information | |
---|---|
Formula | C42H62F3N11O11 |
Molecular Weight | 954.00 |
SMILES | O=C(N[C@@H]([C@H](O)C)C(N[C@@H](CC1=CNC2=CC=CC=C12)C(N[C@@H](CC(C)C)C(N3[C@@H](CCC3)C(N4[C@@H](CCC4)C(N[C@@H](CCCNC(N)=N)C(O)=O)=O)=O)=O)=O)=O)[C@H](C)N.OC(C(F)(F)F)=O |
Target | Complement System |
Product Description | ATWLPPR Peptide TFA, a heptapeptide, acts as a selective neuropilin-1 inhibitor, inhibits VEGF165 binding to NRP-1, used in the research of angiogenesis. ATWLPPR Peptide TFA has potential in reducing the early retinal damage caused by diabetes. |
Format & Storage | |
---|---|
Format | Solid |
Color | White to off-white |
Purity | 99.56% |
Shipping | Room temperature in the continental U.S. Other areas may vary. |
Storage | In solvent: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light) |
Solubility Overview | Soluble in water |
Ace Therapeutics has a team of experts in the field of endocrine and metabolic research, aiming to provide innovative preclinical contract research solutions to cope with diabetes and its complications. We provide customized solutions and technical support, enabling the transformation of promising concepts into innovative treatments, thus accelerating the drug development process of diabetes.